logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls/Updates
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

Press Releases

  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
    • 11 DEC 2017

    PharmaCyte Biotech Meets with Oncology Advisory Board

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it recently met with its Oncology Advisory Board, which was formed to assist in optimizing and finalizing

    Read more →
    • Posted in
    • News
    • 05 DEC 2017

    PharmaCyte Biotech Announces Production of Master Cell Bank

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that the production of the cells necessary to prepare the Master Cell Bank (MCB) has started. This important

    Read more →
    • Posted in
    • News
    • 28 NOV 2017

    PharmaCyte Biotech Announces Successful Completion of Cell Testing for Production of Master Cell Bank

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that Eurofins Lancaster Laboratories, a leading Contract Manufacturing Organization that PharmaCyte selected to prepare its Master Cell Bank

    Read more →
    • Posted in
    • News
    • 16 NOV 2017

    British Columbia Securities Commission Revokes Cease Trade Order on PharmaCyte Biotech Securities

    PharmaCyte Issues Corporate Overview and History LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it is providing a summary overview, corporate history and status report

    Read more →
    • Posted in
    • News
    • 03 NOV 2017

    PharmaCyte Biotech Releases Shareholder Call Playback Information

    LAGUNA HILLS, CA November 3, 2016  – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that an audio recording of the company’s shareholder call, which was held on November 1, 2017, by the Chief Executive

    Read more →
    • Posted in
    • News
    • 29 OCT 2017

    PharmaCyte Biotech Update on Shareholder Call

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that during its upcoming shareholder call PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, will update shareholders on PharmaCyte’s clinical program for pancreatic

    Read more →
    • Posted in
    • News
    • 20 OCT 2017

    PharmaCyte Biotech to Hold Shareholder Call

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Chief Executive Officer Kenneth L. Waggoner will conduct a shareholder call on Wednesday, November 1, 2017, commencing at 4:30 p.m. EDT.

    Read more →
    • Posted in
    • News
    • 17 OCT 2017
    PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight Cancer

    PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight Cancer

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its research partner, the University of Northern Colorado (UNC), has identified an organism whose genome contains the genetic code for production

    Read more →
    • Posted in
    • News
    • 10 OCT 2017

    PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Dr. Raymond C.F. Tong to its Board of Directors. Dr. Tong serves as Chief Executive Officer of Harmony Medical Inc.,

    Read more →
    • Posted in
    • News
    • 13 SEP 2017

    PharmaCyte Biotech Appoints Alan Morell of Creative Management Partners as Strategic Advisor

    LAGUNA HILLS, CA, September 13, 2017 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Alan Morell, the Chairman and Chief Executive Officer

    Read more →
    • Posted in
    • News
  • 1
  • 2
  • 3
  • 4